---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-21-006167"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2021-08-26T23:59:59+00:00"
generated_at: "2026-06-29T07:43:19.829621+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# BioCryst appoints former FDA CDER director Steven Galson to board of directors

## Summary
- Board expanded from 9 to 10; Galson effective Sept 1, 2021, term ends at 2022 annual meeting.
- Galson is former FDA CDER director, acting U.S. surgeon general, and ex-SVP R&D at Amgen.
- Receives automatic grant of 60,000 stock options upon joining, plus 40,000 annually subject to tenure.
- Appointed to Science Committee; compensation per company's director compensation policy.

## SEC filing metadata
- accession: 0001171843-21-006167
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2021-08-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184321006167/0001171843-21-006167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184321006167/f8k_082621.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-21-006167
- JSON: https://secwatch.observer/filing/0001171843-21-006167.json
- Plain text: https://secwatch.observer/filing/0001171843-21-006167.txt

## Key facts
- Executive change
  Steven Galson was appointed as Director at BIOCRYST PHARMACEUTICALS INC.
  - Action: appointed
  - Role: Director
  source text: elected Steven Galson, M.D. to fill the vacancy created by the enlargement of the Board, effective September 1, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184321006167/0001171843-21-006167-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.